Revisiting fosfomycin to treat urinary tract infections in the era of rising carbapenem resistance
Keywords:
Multidrug resistance; Urinary tract infection; Antimicrobial drug resistance; Carbapenems; Uropathogenic Escherichia coliAbstract
Background: Most of the studies on antibiotic resistance are pre-judiced over the use of last-resort antibiotics for Multidrug resistant organisms (MDRO) and fail to acknowledge the effectiveness of older antibiotics. There is a dearth of information regarding the susceptibility of fosfomycin and nitrofurantoin, which are oral alternatives for such infections.
Aims and Objectives: To study the antibiotic susceptibility profile of uropathogenic Escherichia coli and infer whether fosfomycin can be used as an efficient oral option for the management of uncomplicated urinary tract infection (UTI), especially in carbapenem-resistant cases.
Materials and Methods: Clean catch midstream urine samples from cases clinically suspected of UTI received for culture were processed using standard guidelines for microbiological procedures. Antimicrobial sensitivity was performed through the Kirby Bauer disc diffusion method. Discrepant results were confirmed with VITEK 2.
Results: This study reports antimicrobial susceptibility pattern of 100 E. coli isolated from urine samples of patients with signs and symptoms suggestive of UTI. There was a female predominance in the study population and the most affected age group was 20–40 years (52%). Most specimens were received from the obstetrics and gynecology department (32%) followed by General medicine (28%). Higher sensitivity was observed for fosfomycin (97%), amikacin (80%), and meropenem (79%).
Conclusion: Fosfomycin is an oral, safe, and efficient antibiotic for UTI. It is a valuable alternative for outpatient treatment of MDROs causing UTI. Thus, decreasing hospitalization and consequently reducing the financial burden of treatment for the patients.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
